The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers (original) (raw)

Summary

Cotinine is a major metabolite of nicotine in man. Its disposition kinetics has been followed in plasma and saliva from nine nonsmokers, 23 to 56 years of age. Cotinine 5, 10 and 20 mg was given intravenously and orally to each subject, and plasma, saliva and urine samples were collected for 96 h.

The kinetics of cotinine was best described by a multi-compartment model with three distinct phases both in plasma and saliva. Regardless of the mode of administration, there was no indication of dose-dependent kinetics. Mean total plasma clearance was 63.8 ml·h−1·kg−1 and mean renal clearance was 4.7 ml·h−1·kg−1, i.e. only 10% of the dose was excreted unchanged in the urine. The volume of distribution, as calculated from the plasma curves, was slightly greater than the body weight, 1.1 l·kg−1. The concentration of cotinine was 20 to 40% higher in unstimulated mixed saliva than in plasma during the absorption, distribution and elimination phases. As the clearance and distribution values in saliva were directly proportional to the corresponding values in plasma, similar terminal half-life values were obtained in the two body fluids, 15.5 and 16.8 h for plasma and saliva, respectively.

Thus the kinetics of cotinine is linear after intravenous and after oral dosing, and salivary concentrations give the same information about cotinine disposition in the body as do plasma concentrations.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Pilotti Å (1980) Biosynthesis and mammalian metabolism of nicotine. Acta Physiol Scand [Suppl] 479: 13–17
    Google Scholar
  2. Borzelleca JF, Bowman ER, McKennis H (1962) Studies on the respiratory and cardiovascular effects of (−)-cotinine. J Pharmacol Exp Ther 137: 313–318
    Google Scholar
  3. Yamamoto K, Domino EF (1965) Nicotine-induced EEG and behavioral arousal. Int J Neuropharmacol 4: 359–373
    Google Scholar
  4. Benowitz NL, Kuyt F, Jacob P, Jones RT, Osman A-L (1983) Cotinine disposition and effects. Clin Pharmacol Ther 34: 604–611
    Google Scholar
  5. Svensson CK (1987) Clinical pharmacokinetics of nicotine. Clin Pharmacokinet 12: 30–40
    Google Scholar
  6. Curvall M, Enzell CR (1986) Monitoring absorption by means of determination of nicotine and cotinine. Arch Toxicol [Suppl] 9: 88–102
    Google Scholar
  7. Reference deleated
  8. Galeazzi RL, Daenens P, Gugger M (1985) Steady-state concentation of cotinine as a measure of nicotine-intake by smokers. Eur J Clin Pharmacol 28: 301–304
    Google Scholar
  9. Beckett AH, Gorrod JW, Jenner PJ (1972) A possible relation between pKa, and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man. J Pharm Pharmacol 24: 115–120
    Google Scholar
  10. Bowman ER, McKennis H (1963) (-)-Cotinine. Biochem Prep 10: 36–39
    Google Scholar
  11. Curvall M, Kazemi Vala E, Enzell CR (1982) Simultaneous determination of nicotine and cotinine in plasma using capillary column gas chromatography with nitrogen-sensitive detection. J Chromatogr Biomed Appl 232: 368–372
    Google Scholar
  12. Brown RD, Manno JE (1978) ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 67: 1687–1691
    Google Scholar
  13. Benowitz NL, Jacob J (1987) Metabolism, pharmacokinetics and pharmacodynamics of nicotine in man. In: Martin RM, Van Loon GR, Iwamoto ET, Davis L (eds) Tobacco smoking and nicotine. Advances in Behavioral Biology, Vol. 31. Plenum Press, New York
    Google Scholar
  14. Neurath GB, Dunger M, Orth D, Pein FG (1987) Trans-3′-hydroxycotinine as a main metabolite in urine of smokers. Int Arch Occup Environ Health 59: 199–201
    Google Scholar
  15. Kyerematen GA, Damiano MD, Dvorchik BH, Vesell ES (1982) Smoking-induced changes in nicotine disposition: Application of a new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther 32: 769–780
    Google Scholar
  16. Lynch CJ (1984) Half-lives of selected tobacco smoke exposure markers. Eur J Resp Dis [Suppl] 13: 63–67
    Google Scholar
  17. De Schepper PJ, Van Hecken A, Van Rossum JM (1987) Kinetics of cotinine after oral and intravenous administration to man. Eur J Clin Pharmacol 31: 583–588
    Google Scholar
  18. Langone JJ, Van Vunakis HV (1975) Quantitation of cotinine in sera of smokers. Res Commun Chem Pathol Pharmacol 10: 21–28
    Google Scholar
  19. Sepkovic D, Haley NJ (1985) Biomedical applications of cotinine quantitation in smoking related research. Am J Public Health 75: 663–665
    Google Scholar
  20. Gibaldi M, Perrier D (1982) Pharmacokinetics. Drugs and the pharmaceutical Science 15. Marcel Decker, New York
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Research Department, Swedish Tobacco Co., Stockholm, Sweden
    M. Curvall, E. Kazemi-Vala & C. R. Enzell
  2. Units of Clinical Pharmacology, Danderyd and Huddinge Hospitals, Sweden
    C.-E. Elwin
  3. Department of Internal Medicine, Danderyd Hospital, Sweden
    C. Warholm

Authors

  1. M. Curvall
  2. C.-E. Elwin
  3. E. Kazemi-Vala
  4. C. Warholm
  5. C. R. Enzell

Rights and permissions

About this article

Cite this article

Curvall, M., Elwin, CE., Kazemi-Vala, E. et al. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.Eur J Clin Pharmacol 38, 281–287 (1990). https://doi.org/10.1007/BF00315031

Download citation

Key words